2005, Number 1
<< Back Next >>
Dermatología Cosmética, Médica y Quirúrgica 2005; 3 (1)
Intralesional bleomycin in dermatology. Review
Hasson NA, Valdés FR, Murdoch VJ, Muñoz OC
Language: Spanish
References: 38
Page: 15-21
PDF size: 152.84 Kb.
ABSTRACT
Bleomycin is a cytotoxic polipeptide mixture that traditionally has been used for the sistemic treatment
of some cancers. Because of its high selectivity for epithelial cells it has been suggested its intralesional
use for several cutaneous diseases.
We review the treatment of intralesional bleomycin in warts, keloids, Kapósi’s sarcoma, non-melanoma skin
cancer, oral leukoplasia, hemangiomas and cystic hygromas. The results were good and promising, but further
investigations are mandatory and intralesional bleomycin should not be prescribed as a rutinary method.
REFERENCES
Umezawa H, Maeda K, Takeuchi T, Ishizuke M. New antibiotics, bleomycin A and B. J Antibiot A 1966; 19: 200-209
Templeton S, Solomon A, Swerlick R. Intradermal bleomycin injections into Normal Human Skin. Arch Dermatol 1994; 130: 577-583
Chabner B, Allegra C, Curt G, Calabresi P. “Antineoplastic agents”. In: Goodman and Gilman’s The pharmacological basis of therapeutics. 9th edition, McGraw Hill, New York, 1996
Clayman G, Dreiling L. Inyectable modalities as local and regional strategies for head and neck cancer. Hematol Oncol Clin North Am 1999; 13 (4): 787-810
James MP, Collier PM, Aherne W, Hardcastle A, Lovegrove S. Histologic, pharmacologic, and immunocytochemical effects to injection of bleomycin into viral warts. J Am Acad Dermatol 1993; 28: 933-937
Warner D, Flowers F. Plasma levels of bleomycin after intralesional injection. J Am Acad Dermatol 1994; 29: 812
Manz LA, Pelachyk JM. Bleomycin-lidocaine mixture reduces pain of intralesional injection in the treatment of recalcitrant verrucae. J Am Acad Dermatol 1991; 25: 524-526
Sollito RJ, Napoli RC, Gazivoda PL, Hart TJ. A perspective study using bleomycin sulfate in the treatmente of plantar verrucae. J Foot Surg 1989; 28: 141-144
Hayes ME, O’Keefe EJ. Reduced dose of bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol 1986; 15: 1002-1006
Habif JA. “Warts”. In: Habif JA, Clinical Dermatology, 3th ed. Mosby- Yearbook Inc, New York, 1996, 326-334
Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996; 135: 969-971
Tsuji T. Bleomycin iontophoretic therapy for verrucous carcinoma. Arch Dermatol 1991; 127: 973-975
Heller R, Jaroszeski M, Reintgen D, Puleo C, DeConti R, Gilbert R, Glass L. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83: 148-157
Rodríguez-Cuevas S, Barroso-Bravo S, Almarza-Estrada J, Cristóbal- Martínez L, González-Rodríguez E. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001; 32: 273-276
Glass F, Pepine M, Fenske N, Jaroszeski M, Reintgen D, Heller R. Bleomycin-mediated electrochemotherapy of metastatis melanoma. Arch Dermatol 1996; 132: 1353-1357
Ota M, Kawashima M, Mitsuishi T. Multiple Bowen’s disease of the fingers. Eur J Dermatol 2002; 12: 275-277
Silverman S Jr, Gorski M, Lozada F. Oral leukoplakia and malignant transformation. A follow up study of 257 patients. Cancer 1984; 53: 563-568
Chu FWK, Silverman S Jr, Dedo HH. CO2 laser treatment of oral leukoplakia. Laryngoscope 1988; 98: 125-130
Wong F, Epstein J, Millner A. Treatment of oral leukoplakia with topical bleomycin. Cancer 1989; 64: 361-365
Epstein J, Gorski M, Wong F, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer 1998; 83: 629-634
Gascon P, Schwartz R. Kaposi´s sarcoma. Dermatol Clin 2000, 18 (1): 169-174
O´Connor P, Scadden D. Aids Oncology. Infect Dis Clin North Am 2000, 14 (4): 945-965
Poignonec S et al. Intralesional bleomycin for acquired immunodeficiency syndrome- associated cutaneous Kaposi’s sarcoma. Arch Dermatol 1995; 131: 228
Boudreaux AA, Smith LL, Cosby CD et al. Intralesional vinblastine for cutaneous Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 1993; 28: 61-65
Shaffer J, Taylor S, Cook-Bolden F. Keloid scars: A review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46: S63-97
España A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg 2001; 27 (1): 23-27
Bodock I, Brun P. Treatment of keloid with intralesional bleomycin. Ann Dermatol Venereol 1996; 123 (12): 791-794
Zheng QT. Local injection of Bleomycin A 5 in children with hemangiomas. Analysis of 210 cases. Zhonghua Wai Ke Za Zhi 1991; 29 (5): 290-291
Sarihan H, Mocan H, Yildiz K, Abes M, Akyazici R. A new treatment with bleomycin for complicated cutaneous hemangioma in children. Eur J Pediatr Surg 1997; 7 (3): 158-162
Kullendorff CM. Efficacy of bleomycin treatment for symptomatic hemangiomas in children. Pediatr Surg Int 1997; 12 (7): 526-528
Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg 1995; 30 (9): 1282-1287
Miller RA. Nail dystrophy following intralesional injections of bleomycin for a periungueal wart. Arch Dermatol 1984; 120: 963-964
Abess A, Keel D, Graham B. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 2003; 139: 337-339
Smith EA, Harper FE, LeRoy EC. Raynaud’s phenomenon of a single digit following local intradermal bleomycin sulfate injection. Arthritis Rheum 1985; 28: 459-467
Gregg LJ. Intralesional bleomycin and Raynaud’s phenomenon. J Am Acad Dermatol 1992; 26: 279-280
Epstein E. Intralesional bleomycin and Raynaud’s phenomenon. J Am Acad Dermatol 1991; 24: 786-786
Vanhootenghem O, Richert B, de la Brassinne M. Raynaud phenomenon after treatment verruca vulgaris of the sole with intralesional injection of bleomycin. Pediatr Dermatol 2001; 18: 249-251
Allen A, Fosko S. Lymphangitis as a complication of intralesional bleomycin therapy. J Am Acad Dermatol 1998; 39: 295-297